Skip to content

Homoeopathic treatment in adenomyosis

Role of individualized homoeopathic medicine in the treatment of adenomyosis: An open label prospective clinical trial - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/067451
Enrollment
30
Registered
2024-05-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N800- Endometriosis of uterus

Interventions

Intervention1: Individualized Homoeopathic Medicine: Homoeopathic Medicine will be prescribed according to the symptom similarity for a period of 6 months. Medicine will be prescribed in both centesi

Sponsors

Arup Kumar Mondal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Female patient with a positive diagnostic finding for adenomyosis. 2. Women of age group 18-60 years. 3. Patients willing to give consent for participating in the study. 4. Patients who can read Bengali and/or Hindi and/or English.

Exclusion criteria

Exclusion criteria: 1. Pregnant women or lactating mothers. 2. Diagnosed cases of unstable psychiatric illness or other systemic disease affecting quality of life or some life-threatening illness. 3. Patients not willing to participate in the study. 4. Substance abuse and/or dependence.

Design outcomes

Primary

MeasureTime frame
Numeric Rating Scale (NRS) Measurement for menstrual pain. The NRS is one of the most commonly used scales having a range from 0-10, where ‘0’ denotes no pain and ‘10’ denotes worst possible pain imaginable. • Pictorial blood loss assessment chart (PBAC) measurement for menstrual bleeding. The chart consists of a series of diagrams which depict staining, clots and flooding. The number of sanitary pad/tampons used each day during menstruation is recorded by placing a tally mark in the next box. For scoring row total is multiplied by multiplying factor for each row.Timepoint: At baseline and 6 month

Secondary

MeasureTime frame
n attempt will be made to show changes in the pathology through lab investigations – USG (lower abdomen and pelvis)/ TVS/MRI (lower abdomen and pelvis)Timepoint: At baseline and 6 month

Countries

India

Contacts

Public ContactArup Kumar Mondal

National Institute of Homoeopathy

ushauchat@gmail.com9830966265

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026